Abstract 5234: A phase I study of HMPL-689, a small molecule selective inhibitor of phosphoinositide 3-kinase-delta, inpatients with relapsed or refractory lymphoma
Lawrence, Tunde, Khullar, Alisha, Yang, Weiss, Hahka-Kemppinen, Marjo, Kania, Marek, Su, Weigou
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
Abstract 5239: A phase I study of HMPL-523, a small molecule, selective inhibitor of spleen tyrosine kinase, inpatients with relapsed or refractory lymphoma
Lawrence, Tunde, Khullar, Alisha, Yang, Weiss, Hahka-Kemppinen, Marjo, Kania, Marek, Su, Weigou
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
Abstract CT107: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Efficacy and safety results from phase II of the TRINITI-1 study
Moulder, Stacy, Karuturi, Megan, Yardley, Denise A., Wright, Gail Shaw, Hurvitz, Sara, Moroose, Rebecca, Sanft, Tara, Ma, Cynthia, Zelnak, Amelia, DeMichele, Angela, Clark, Amy, Purkayastha, Das, Khullar, Alisha, Caria, Nicola, Bardia, Aditya
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Get full text
Journal Article
Abstract CT144: Safety and efficacy of HMPL-523 (Syk inhibitor) in patients with relapsed or refractory lymphoma
Strati, Paolo, Gonzalez-Barca, Eva, Morillo, Daniel, Ahmed, Sairah, Chraniuk, Dominik, Leppa, Sirpa, Vicente, Fatima de la Cruz, Centkowski, Piotr, Pillai, Rathi N., Nanda, Shivani, Khullar, Alisha, Hahka-Kemppinen, Marjo, Jayaprakash, Vijayvel, Gritti, Giuseppe
Published in Cancer research (Chicago, Ill.) (05.04.2024)
Published in Cancer research (Chicago, Ill.) (05.04.2024)
Get full text
Journal Article